StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

Stock analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

Shares of NASDAQ AKTX opened at $0.94 on Friday. The company’s fifty day moving average price is $1.15 and its 200 day moving average price is $2.00. Akari Therapeutics has a 1 year low of $0.85 and a 1 year high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.